96．Takenaga M, Igarashi R, Higashi M, Nakayama T, Yuki K, Mizushima
Y． Effect of a soluble pseudo-receptor on verotoxin 2-induced toxicity．Ｊ
Infect Chemother 6, 21-25, 2000．
97．Takenaga M, Igarashi R, Mizushima Y． Possibility of lipid microsphere-encapsulated Y-24180 as an injectable drug and an inhaler for the treatment of bronchoconstriction. Allergology international 49, 143-149, 2000．
98．Yamazaki R, Kawai S, Mizushima Y, Matsuzaki T, Hashimoto S, Yokokura T, Ito A．A major metabolite of aceclofenac, 4'-hydroxy aceclofenac, suppresses the production of interstitial pro-collagenase/proMMP-1 and pro-stromelysin-1/proMMP-3 by human rheumatoid synovial cells. Inflamm res 49,133-138, 2000．
99．Aoshima H, Yoshida T, Kobayashi S, Mizushima Y, Kawai S． Genomic DNA analysis of thyrotropin receptor in a family with hereditary hyperthyroidism. Endocrine Journal 47(3),365-372, 2000．
100．Nakajima H, Ishizaka N, Hangaishi M, Taguchi J, Itoh J, Igarashi R, Mizushima Y, Nagai R, Ohno M． Lecithinized copper, zinc-superoxide dismutase ameliorates prolonged hypoxia-induced injury of cardiomyocytes.Free Radical Biology & Medicine 29(1), 34-41, 2000．
101．Suzuki Y, Nakagawa M, Sato F, Iichikawa Y, Mizushima Y． A primary adrenal steroid, 11β-hydroxyandrostenedione, has an osteotropic effect and little androgenic activity. Journal of steroid biochemistry & Molecular biology 74, 203-211, 2000．
102．Higaki M, Azechi Y, Takase T, Igarashi R, Nagahara S, Sano A, Fujioka K, Nakagawa N, Aizawa C, Mizushima Y．Collagen minipellet as controlled release delivery system for tetanus and diphtheria toxoid. Vaccine 19, 3091- 3096, 2001．
103．Igarashi R, Takeuchi J, Kitagawa A, Matsumoto K, Mizushima Y. Marked hypotensive and blood flow-increasing effects of a new lipo-PGE1(lipo-AS013)due to vascular wall targeting. J Controlled Release 71(2), 157-164, 2001.
104．Nakajima H, Hangaishi M, Ishizaki N, Taguchi J, Igarashi R, Mizushima Y, Nagai R, and Ohno N. Lecithnized copper, zinc-superoxide dismutase ameliorates ischemia-induced myocardial damage. Life Sci,69(8), 935-944, 2001.
105．Tanihara M, Suzuki Y, Yamamoto E, Noguchi A, and Mizushima Y. Sustained release of basic fibroblast growth factor and angiogenesis in a novel covalently croslinked gel heparin and alginate. J Biomed Mater Res 56(2), 216-221, 2001.
106．Szuki Y, Tsutsumi Y, Nakagawa M, Suzuki H, Matsushita K, Beppu M, Aoki H, Ichikawa Y, Mizushima Y. Osteoclast-Like cells in an in vitro model of bone destruction by rheumatoid synovium. Rheumatol,40(6), 673-682, 2001.
2002〜2004
107．Takenaga M, Yamaguchi Y, Kitagawa A, Ogawa Y, Mizushima Y, Igarashi R. A novel sustained-release formulation of insulin with dramatic reduction in initial rapid release. J Controlled Release 79, 81-91, 2002.
108．Shoji Y, Shimada J,Mizushima Y. Drug delivery system to control infectious diseases. Curr Pharm Design 8, 455-465, 2002.
109．Yamaguchi Y, Takenaga M, Kitagawa A, Ogawa Y, Mizushima Y, Igarashi R. Insulin-loaded biodegradable PLGA microcapsules-initial burst release controlled by the hydrophilic additives-J controlled Release. 81, 235-249, 2002
110．Takenaga M, Yamaguchi Y, Kitagawa A, Ogawa Y, Mizushima Y, Igarashi R. A novel insulin formulation can keep providing steady levels of insulin for much longer periods. J Pharm. Pharmacol 54, 1189-1194, 2002
111．Paula A. Phipps, Miles R. Stanford, Jia-Bin Sun, Bao-Guo Xiao, Jan Holmgren, Thomas Shinnick, Adam Hasan, Yutaka Mizushima, Thomas Lehner. Prevention of mucosally induced uveitis with a HSP60-derived peptide linked to cholera toxin B subunit. Eur.J. Immunol.33,224-232, 2003
112. Toshiyuki Ikoma, Keiji Kurashima, Yasushi Swestugu, Junzo Tanaka, Yutaka Mizushima. Spherical Microparticles of Porous Hydroxyapatite Covered with Vaterite. Chemistry letters. Submitted 2003
113.Takuya Suzuki, Sotaro Ooto, Tadamichi Akagi, Kaori Amemiya, Rie Igarashi, Yutaka Mizushima, and Masayo Takahashi. Effects of prolonged delivery of brain-derived neurotrophic factor on the fate of neural stem cells transplanted into the developing rat retina. Biochemical and Biophysical Research Communications 309,843-847,2003
2005〜現在
114.Megumu Higaki, Mitsuharu Takatsu, Yutaka Mizushima. Treatment of experimental arthritis with PLGA nanoparticles encapsulating betamethasone sodium phosphate. Ann Rheum Dis. 64(8),1132-6,2005
115.Mitsuharu Takatsu, Megumu Higaki, Hirotsugu Kinoshita, Yutaka Mizushima and Izumi Koizuka. Ear involvement in patients with Rheumatoid Arthritis. Otol Neurotol. 26,755-761,2005
116.Tamura T, Kita T, Nakagawa T, Endo T, Kim T, Ishihara T, Mizushima Y, Higaki M, Ito J. Drug Delivery to the Cochlea Using PLGA Nanoparticles. Laryngoscope 115,2000-2005,2005
117.Ishihara T, Izumo N, Higaki M, Shimada E, Hagi T, Mine L, Ogawa Y, Mizushima Y. Role of zinc in formation of PLGA/PLA nanoparticles encapsulating betamethasone phosphate and its release profile. J Control Release 105,68-76,2005
118.Yamaguchi Y, Nagasawa T, Nakamura N, Takenaga M, Mizoguchi M, Kawai S, Mizushima Y, Igarashi R. Successful treatment of photodamaged skin of nano-scale atRA particles using a novel transdermal delivery. J Control Release 104(1),29-40,2005
119.Higaki M, Ishihara T, Izumo N, Takatsu M, Mizushima Y, Treatment of experimental arhtritis with poly (D,L-lactic/glycolic acid) nanoparticles encapsulating betamethasone sodium phosphate. Ann Rheum Dis 64(8),1132-6,2005
120.Ueno Y, Futagawa H, Takagi Y, Ueno A, Mizushima Y. Drug-incorporating calcium carbonate nanoparticles for a new delivery system. J Control Release 103,93-8,2005
121.Sakai T, Kohno H, Ishihara T, Higaki M, Saito S, Matsushima M, Mizushima Y, Kitahara K. Treatment of experimental autoimmune uveoretinitis with poly (lactic acid) nanoparticles encapsulating betamethasone phosphate. Experimental Eye Research 82,657-663,2006
122.Yutaka Mizushima, Toshiyuki Ikoma, Jyunzo Tanaka, Keiko Hoshi, Tsutomu Ishihara, Yasuaki Ogawa, Akinori Ueno. Injectable porous hydroxyapatite microparticles as a new carrier for protein and lipophilic drugs. J. Controlled Release 110,260-265,2006
123.Imamura Y, Noda S, Hashizume K, Shinoda K, Yamaguchi N, Utiyama S, Shimizu T, Mizushima Y, Shirasawa T, Tsubota K. Drusen,choridal neovascularization,and ritinal pigment epithelium dysfunction in SOD1-deficient mice:A model of age-related macular degeneration. 103(30),11282-7,2006
124.Higaki M, Kameyama M, Udagawa M, Ueno Y, Yamaguchi Y, Igarashi R, Ishihara T, Mizushima Y. Transdermal delivery of CaCO3-nanoparticles containing insulin. Diabetes Technol Ther. 8(3),369-74,2006
125.Masako Hara, Yutaka Mizushima,et al. Efficacy and safety of iguratimod compared with placebo and salazosulfapyridine in active rheumatoid arthritis:a controlled, multicenter, double-blind, parallel-group study. Jap. Colleage Rheum. 17, 1-9, 2007
126.Masako Hara, Yutaka Mizushima,et al. Long-term safety study of iguratimod in patients with rheumatoid arthritis. Jap. Colleage Rheum. 17,10-16,2007
